CoChat

Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinson’s disease; however, individuals with Parkinson’s disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinson’s disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinson’s disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinson’s disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more ‘high risk factors’ for a genetic aetiology: early onset (<50 years), high-risk ancestry (Ashkenazi Jewish/Basque/North African Berber), an affected first-degree relative; and, importantly, in 9.1% of people with none of these risk factors. Reportable variants in GBA1 were identified in 7.7% of all participants; 2.4% in LRRK2; 2.1% in PRKN; 0.1% in SNCA; and 0.2% in PINK1, PARK7 or VPS35 combined. Variants in more than one of the seven genes were identified in 0.4% of participants. Approximately 13% of study participants had a reportable genetic variant, with a 9% yield in people with no high-risk factors. This supports the promotion of universal access to genetic testing for Parkinson’s disease, as well as therapeutic trials for GBA1 and LRRK2-related Parkinson’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awae142

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PD GENEration heat map. Heat map showing broad enrolment of participants into PD GENEration by county in the US, Puerto Rico and the Dominican Republic. Use of telemedicine allowed for enrolment of participants from all 50 states, representing both urban and rural areas.
Figure 1 PD GENEration heat map. Heat map showing broad enrolment of participants into PD GENEration by county in the US, Puerto Rico and the Dominican Republic. Use of telemedicine allowed for enrolment of participants from all 50 states, representing both urban and rural areas.CC BY · PubMed Central
Figure 2 Reportable results. Pie chart (left) depicting overall positivity rate for reportable variants in a single gene or multiple genes among 8301 participants. Right: Categorization of single gene variants for the PD GENEration seven-gene panel. Values are number of participants followed by percentage of total. CPHet = compound heterozygous; Hom = homozygous; Het = heterozygous.
Figure 2 Reportable results. Pie chart (left) depicting overall positivity rate for reportable variants in a single gene or multiple genes among 8301 participants. Right: Categorization of single gene variants for the PD GENEration seven-gene panel. Values are number of participants followed by percentage of total. CPHet = compound heterozygous; Hom = homozygous; Het = heterozygous.CC BY · PubMed Central
Figure 3 Variant level results. Variant level representation of results reportable to participants (left), compared to disease relevant results (right), which included GBA1 T408M and excluded heterozygous (Het) carriers of recessive genes. Individuals positive for multiple genes are counted in both gene categories resulting in adjusted totals between graphs. Variant counts are in the heterozygous state unless otherwise specified. Different variant inclusions between graphs resulted in shifts of some individuals from heterozygous to compound heterozygous (CPhet) categories (e.g. two individuals with GBA1 N409S/T369M represented as N370S on the left and compound heterozygous on the right). Hom = homozygous.
Figure 3 Variant level results. Variant level representation of results reportable to participants (left), compared to disease relevant results (right), which included GBA1 T408M and excluded heterozygous (Het) carriers of recessive genes. Individuals positive for multiple genes are counted in both gene categories resulting in adjusted totals between graphs. Variant counts are in the heterozygous state unless otherwise specified. Different variant inclusions between graphs resulted in shifts of some individuals from heterozygous to compound heterozygous (CPhet) categories (e.g. two individuals with GBA1 N409S/T369M represented as N370S on the left and compound heterozygous on the right). Hom = homozygous.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Metadata

Authors
Cook, L., Verbrugge, J., Schwantes-An, T.-H., Schulze, J., Foroud, T., Hall, A., Marder, K. S., Mata, I. F., Mencacci, N. E., Nance, M. A., Schwarzschild, M. A., Simuni, T., Bressman, S., Wills, A.-M., Fernandez, H. H., Litvan, I., Lyons, K. E., Shill, H. A., Singer, C., Tropea, T. F., Vanegas Arroyave, N., Carbonell, J., Cruz Vicioso, R., Katus, L., Quinn, J. F., Hodges, P. D., Meng, Y., Strom, S. P., Blauwendraat, C., Lohmann, K., Casaceli, C., Rao, S. C., Ghosh Galvelis, K., Naito, A., Beck, J. C., & Alcalay, R. N.
Affiliations
  • Indiana University School of Medicine (US)
  • Parkinson's Foundation (US)
  • Columbia University Irving Medical Center (US)
  • Cleveland Clinic (US)
  • Northwestern University (US)
  • Struthers Parkinson’s Center, Golden Valley , MN 55427 , USA
  • Massachusetts General Hospital (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of California San Diego (US)
  • University of Kansas Medical Center (US)
  • Barrow Neurological Institute (US)
  • University of Miami (US)
  • University of Pennsylvania (US)
  • Department of Neurology, Baylor College of Medicine , Houston, TX 77030 , USA
  • Centro Cardioneuro Oftalmológico y Trasplante , Santo Domingo 10306, República Dominicana
  • Medicina Interna, Clínica Unión Médica del Norte , Santiago de los Caballeros 51000, República Dominicana
  • Oregon Health & Science University (US)
  • Temple Lung Center (US)
  • Illumina (United States) (US)
  • National Institutes of Health (US)
  • University of Lübeck (DE)
  • University of Rochester Medicine (US)
  • Parkinson’s Foundation , NewYork, NY 10018 , USA
Corresponding author
Alcalay, Roy N
Venue
Brain
Published
2024-07-30
Volume
147
Issue
8
Pages
2668-2679
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4401158013
Cited by
108
References
28
Citations by year
2026: 44 · 2025: 55 · 2024: 9
FWCI
28.90
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
Parkinson’s Foundation
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease, genetic testing, genetic counseling, LRRK2, GBA1, Parkin, SNCA, PINK1, DJ-1, VPS35, genetic risk variants, genetic aetiology, genetic ancestry, early-onset Parkinson's disease, North America, Puerto Rico, Dominican Republic
MeSH terms
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Deglycase DJ-1, PTEN-Induced Putative Kinase, Adult, Aged, Canada, Female, Genetic Counseling, Genetic Testing, Glucosylceramidase, Humans, Male, Middle Aged, North America, Parkinson Disease, Protein Kinases, United States, Genetic Variation, Genetic Predisposition to Disease, Disclosure, Vesicular Transport Proteins, Ubiquitin-Protein Ligases, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.